Selenium status and cardiovascular diseases

Meta-analysis of prospective observational studies and randomized controlled trials

X. Zhang, C. Liu, J. Guo, Yiqing Song

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background/Objectives:Selenium was thought to have a role in cardiovascular disease (CVD) owing to its antioxidant properties; however, evidence from observational studies and randomized controlled trials (RCTs) has been inconsistent and controversial. We thus conducted a meta-analysis to assess the discrepancies between observational and randomized trial evidence.Subjects/Methods:We searched MEDLINE and EMBASE for eligible prospective studies regarding the relationship between selenium and CVD up to 15 December 2013 and finally included 16 prospective observational studies and 16 RCTs. Random effects model was used to estimate the pooled relative risk (RR). Generalized least-squares trend test and restricted cubic spline model were performed to assess a linear and a nonlinear dose-response relationship.Results:Our meta-analysis of prospective studies showed a nonlinear relationship of CVD risk with blood selenium concentrations across a range of 30-165 μg/l and a significant benefit of CVD within a narrow selenium range of 55-145 μg/l. Our meta-analyses of RCTs showed that oral selenium supplements (median dose: 200 μg/day) for 2 weeks to 144 months significantly raised the blood selenium concentrations by 56.4 μg/l (95% confidence interval (CI): 40.9, 72.0 μg/l), whereas oral selenium supplements (median: 100 μg/day) for 6 to 114 months caused no effect on CVD (RR=0.91; 95% CI: 0.74, 1.10).Conclusions:Our meta-analysis in prospective studies demonstrated a significant inverse association between selenium status and CVD risk within a narrow selenium range and a null effect of selenium supplementation on CVD was observed in RCTs. These findings indicate the importance of considering selenium status, dose and safety in health assessment and future study design.

Original languageEnglish (US)
Pages (from-to)162-169
Number of pages8
JournalEuropean Journal of Clinical Nutrition
Volume70
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Selenium
Observational Studies
Meta-Analysis
Cardiovascular Diseases
Randomized Controlled Trials
Prospective Studies
Confidence Intervals
Least-Squares Analysis
MEDLINE
Antioxidants
Safety

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Selenium status and cardiovascular diseases : Meta-analysis of prospective observational studies and randomized controlled trials. / Zhang, X.; Liu, C.; Guo, J.; Song, Yiqing.

In: European Journal of Clinical Nutrition, Vol. 70, No. 2, 01.02.2016, p. 162-169.

Research output: Contribution to journalArticle

@article{6073d51d1b6d4e06926c256a2bb1e535,
title = "Selenium status and cardiovascular diseases: Meta-analysis of prospective observational studies and randomized controlled trials",
abstract = "Background/Objectives:Selenium was thought to have a role in cardiovascular disease (CVD) owing to its antioxidant properties; however, evidence from observational studies and randomized controlled trials (RCTs) has been inconsistent and controversial. We thus conducted a meta-analysis to assess the discrepancies between observational and randomized trial evidence.Subjects/Methods:We searched MEDLINE and EMBASE for eligible prospective studies regarding the relationship between selenium and CVD up to 15 December 2013 and finally included 16 prospective observational studies and 16 RCTs. Random effects model was used to estimate the pooled relative risk (RR). Generalized least-squares trend test and restricted cubic spline model were performed to assess a linear and a nonlinear dose-response relationship.Results:Our meta-analysis of prospective studies showed a nonlinear relationship of CVD risk with blood selenium concentrations across a range of 30-165 μg/l and a significant benefit of CVD within a narrow selenium range of 55-145 μg/l. Our meta-analyses of RCTs showed that oral selenium supplements (median dose: 200 μg/day) for 2 weeks to 144 months significantly raised the blood selenium concentrations by 56.4 μg/l (95{\%} confidence interval (CI): 40.9, 72.0 μg/l), whereas oral selenium supplements (median: 100 μg/day) for 6 to 114 months caused no effect on CVD (RR=0.91; 95{\%} CI: 0.74, 1.10).Conclusions:Our meta-analysis in prospective studies demonstrated a significant inverse association between selenium status and CVD risk within a narrow selenium range and a null effect of selenium supplementation on CVD was observed in RCTs. These findings indicate the importance of considering selenium status, dose and safety in health assessment and future study design.",
author = "X. Zhang and C. Liu and J. Guo and Yiqing Song",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/ejcn.2015.78",
language = "English (US)",
volume = "70",
pages = "162--169",
journal = "European Journal of Clinical Nutrition",
issn = "0954-3007",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Selenium status and cardiovascular diseases

T2 - Meta-analysis of prospective observational studies and randomized controlled trials

AU - Zhang, X.

AU - Liu, C.

AU - Guo, J.

AU - Song, Yiqing

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background/Objectives:Selenium was thought to have a role in cardiovascular disease (CVD) owing to its antioxidant properties; however, evidence from observational studies and randomized controlled trials (RCTs) has been inconsistent and controversial. We thus conducted a meta-analysis to assess the discrepancies between observational and randomized trial evidence.Subjects/Methods:We searched MEDLINE and EMBASE for eligible prospective studies regarding the relationship between selenium and CVD up to 15 December 2013 and finally included 16 prospective observational studies and 16 RCTs. Random effects model was used to estimate the pooled relative risk (RR). Generalized least-squares trend test and restricted cubic spline model were performed to assess a linear and a nonlinear dose-response relationship.Results:Our meta-analysis of prospective studies showed a nonlinear relationship of CVD risk with blood selenium concentrations across a range of 30-165 μg/l and a significant benefit of CVD within a narrow selenium range of 55-145 μg/l. Our meta-analyses of RCTs showed that oral selenium supplements (median dose: 200 μg/day) for 2 weeks to 144 months significantly raised the blood selenium concentrations by 56.4 μg/l (95% confidence interval (CI): 40.9, 72.0 μg/l), whereas oral selenium supplements (median: 100 μg/day) for 6 to 114 months caused no effect on CVD (RR=0.91; 95% CI: 0.74, 1.10).Conclusions:Our meta-analysis in prospective studies demonstrated a significant inverse association between selenium status and CVD risk within a narrow selenium range and a null effect of selenium supplementation on CVD was observed in RCTs. These findings indicate the importance of considering selenium status, dose and safety in health assessment and future study design.

AB - Background/Objectives:Selenium was thought to have a role in cardiovascular disease (CVD) owing to its antioxidant properties; however, evidence from observational studies and randomized controlled trials (RCTs) has been inconsistent and controversial. We thus conducted a meta-analysis to assess the discrepancies between observational and randomized trial evidence.Subjects/Methods:We searched MEDLINE and EMBASE for eligible prospective studies regarding the relationship between selenium and CVD up to 15 December 2013 and finally included 16 prospective observational studies and 16 RCTs. Random effects model was used to estimate the pooled relative risk (RR). Generalized least-squares trend test and restricted cubic spline model were performed to assess a linear and a nonlinear dose-response relationship.Results:Our meta-analysis of prospective studies showed a nonlinear relationship of CVD risk with blood selenium concentrations across a range of 30-165 μg/l and a significant benefit of CVD within a narrow selenium range of 55-145 μg/l. Our meta-analyses of RCTs showed that oral selenium supplements (median dose: 200 μg/day) for 2 weeks to 144 months significantly raised the blood selenium concentrations by 56.4 μg/l (95% confidence interval (CI): 40.9, 72.0 μg/l), whereas oral selenium supplements (median: 100 μg/day) for 6 to 114 months caused no effect on CVD (RR=0.91; 95% CI: 0.74, 1.10).Conclusions:Our meta-analysis in prospective studies demonstrated a significant inverse association between selenium status and CVD risk within a narrow selenium range and a null effect of selenium supplementation on CVD was observed in RCTs. These findings indicate the importance of considering selenium status, dose and safety in health assessment and future study design.

UR - http://www.scopus.com/inward/record.url?scp=84956913376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956913376&partnerID=8YFLogxK

U2 - 10.1038/ejcn.2015.78

DO - 10.1038/ejcn.2015.78

M3 - Article

VL - 70

SP - 162

EP - 169

JO - European Journal of Clinical Nutrition

JF - European Journal of Clinical Nutrition

SN - 0954-3007

IS - 2

ER -